During an investor day Thursday, Moderna’s R&D chief Stephen Hoge detailed plans for the famed biotech to trim R&D spending in preparation for the launch of up to 10 new products.
Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028 Read More »
It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our domestic manufacturing capabilities.
BIOSECURE Act Targets China but Fails to Address Fallout for US Biopharma Read More »
Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales or an M&A.
Oncternal to Lay Off 37% of Employees, Including CMO Read More »
Apple is the first company to receive authorization for over-the-counter hearing aid software.
Apple wins FDA nod for hearing aid software for certain Airpods Read More »
IU Health Plans will operate under the Anthem Blue Cross and Blue Shield brand after the deal closes, which is expected at the end of 2024.
Elevance to acquire Indiana University Health’s insurance business Read More »
El autoconsumo fotovoltaico en los hogares españoles ha experimentado un notable crecimiento en los últimos años. Esto se debe a varios factores, como la búsqueda de energías renovables que reduzcan el consumo energético y el impacto ambiental …
Las claves del crecimiento del autoconsumo fotovoltaico Read More »
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for lenacapavir as a pre-exposure prophylactic option for human immunodeficiency virus.
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings Read More »
One patient developed elevated liver blood tests after receiving Astellas Pharma’s non-hormonal small molecule blocker, leading the regulator to add a warning to the drug’s label.
Astellas’ Hot Flash Drug Veozah Slapped With Another FDA Warning for Liver Injury Read More »
BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about Neurocrine Biosciences’ developmental efforts moving forward.
Neurocrine Scraps Schizophrenia Candidate After Phase II Failure Read More »
Tecentriq Hybreza, which combines Roche’s Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology, is being touted as the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy.
Roche Gains PD-1 Edge on Merck With FDA Nod for Subcutaneous Tecentriq Read More »
